רבלימיד 25 מג Izrael - hebrejština - Ministry of Health

רבלימיד 25 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

רבלימיד 25 מג Izrael - hebrejština - Ministry of Health

רבלימיד 25 מג

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

דספרל 0.5 גרם Izrael - hebrejština - Ministry of Health

דספרל 0.5 גרם

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

אקסג'ייד 125 מג Izrael - hebrejština - Ministry of Health

אקסג'ייד 125 מג

novartis israel ltd - deferasirox - טבליות ניתנות לפיזור - deferasirox 125 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration (lic) >5 mg fe/g dry weight (dw) following mri and serum ferritin >800 nanogram/ml).

אקסג'ייד 500 מג Izrael - hebrejština - Ministry of Health

אקסג'ייד 500 מג

novartis israel ltd - deferasirox - טבליות ניתנות לפיזור - deferasirox 500 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration (lic) >5 mg fe/g dry weight (dw) following mri and serum ferritin >800 nanogram/ml).

אקסג'ייד 250 מג Izrael - hebrejština - Ministry of Health

אקסג'ייד 250 מג

novartis israel ltd - deferasirox - טבליות ניתנות לפיזור - deferasirox 250 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration (lic) >5 mg fe/g dry weight (dw) following mri and serum ferritin >800 nanogram/ml).

טייקרב Izrael - hebrejština - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

פרינג'קט Izrael - hebrejština - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial - ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. the diagnosis must be based on laboratory tests.

דספרל 0.5 גרם Izrael - hebrejština - Ministry of Health

דספרל 0.5 גרם

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

פרילידן Izrael - hebrejština - Ministry of Health

פרילידן

halperin n.h. medic ltd, israel - lidocaine; prilocaine - קרם - prilocaine 25 mg / 1 g; lidocaine 25 mg / 1 g - prilocaine